ImmunoCellular Therapeutics Ltd
OTC:IMUC
ImmunoCellular Therapeutics Ltd
OTC:IMUC
Price:
0.129
USD
-27.93%
Market Closed
Market Cap:
$16.3m
Balance Sheet
Balance Sheet Decomposition
ImmunoCellular Therapeutics Ltd
ImmunoCellular Therapeutics Ltd
Balance Sheet Decomposition is not available for
ImmunoCellular Therapeutics Ltd
ImmunoCellular Therapeutics Ltd
Balance Sheet
ImmunoCellular Therapeutics Ltd
ImmunoCellular Therapeutics Ltd
Currency: USD
| Dec-2010 | Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2020 | Dec-2021 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
5
|
7
|
26
|
28
|
23
|
23
|
11
|
7
|
0
|
1
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Cash Equivalents |
5
|
7
|
26
|
28
|
23
|
23
|
11
|
7
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
1
|
1
|
1
|
2
|
2
|
0
|
0
|
0
|
|
| Total Current Assets |
5
|
7
|
27
|
28
|
24
|
25
|
13
|
7
|
0
|
2
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
1
|
5
|
3
|
0
|
0
|
0
|
|
| Total Assets |
5
N/A
|
7
+33%
|
27
+278%
|
29
+7%
|
25
-13%
|
30
+19%
|
17
-44%
|
7
-59%
|
0
-96%
|
2
+525%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
0
|
1
|
1
|
1
|
0
|
1
|
1
|
2
|
0
|
0
|
|
| Accrued Liabilities |
0
|
0
|
0
|
1
|
1
|
1
|
2
|
1
|
0
|
0
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
0
|
2
|
1
|
1
|
1
|
2
|
3
|
2
|
0
|
0
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
|
| Other Liabilities |
3
|
2
|
3
|
1
|
1
|
6
|
8
|
0
|
0
|
0
|
|
| Total Liabilities |
3
N/A
|
4
+29%
|
4
+1%
|
2
-38%
|
2
-24%
|
8
+343%
|
11
+29%
|
2
-78%
|
0
-94%
|
3
+2 294%
|
|
| Equity | |||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
23
|
29
|
43
|
52
|
61
|
74
|
96
|
116
|
1
|
7
|
|
| Additional Paid In Capital |
25
|
32
|
66
|
78
|
85
|
96
|
102
|
121
|
2
|
5
|
|
| Total Equity |
2
N/A
|
3
+38%
|
23
+614%
|
26
+15%
|
23
-12%
|
22
-7%
|
6
-72%
|
5
-24%
|
0
-97%
|
2
N/A
|
|
| Total Liabilities & Equity |
5
N/A
|
7
+33%
|
27
+278%
|
29
+7%
|
25
-13%
|
30
+19%
|
17
-44%
|
7
-59%
|
0
-96%
|
2
+525%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
4
|
113
|
113
|
|
Switch to:
Switch to:
See Also
Discover More
